Drugs / ET140202-T cell
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03965546 | May 2019 → Jun 2021 | hepatocellular carcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ET140202-T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03965546 ↗ |
| Known as | ET140202 | “Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct by intravenous (IV) infusion” NCT03965546 ↗ |
| Modality | Cell therapy | “Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct” NCT03965546 ↗ |
| Route | Intravenous | “autologous ET140202-T cell administered by intravenous (IV) infusion” NCT03965546 ↗ |
| Target | AFP | “The molecular target for ET140202-T cells is HLA-A02 complexed with a HLA-A02-restricted peptide of alpha fetoprotein (AFP)” NCT03965546 ↗ |